NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

HE4 in the Diagnostic Approach of Endometrial Cancer in Patients With Postmenopausal Bleeding

UnknownN/A

Sponsor: Nantes University Hospital

Conditions: Endometrial Neoplasms, Postmenopause, Uterine Hemorrhage, Cancer Biomarker, CA 125 Antigen

Interventions: Patients with Post menopausal bleeding, CA125 and HE4 assays

Countries: France

This study aims to explore the sensitivity of an innovative marker, HE4, in the diagnosis approach of endometrial cancer in case of postmenopausal bleedings.

Eligibility overview

Sex: FEMALE

Age: 18 Years to —

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* Patient with postmenopausal bleeding
* Patient requiring hysteroscopy or hysterectomy
* No objection from the patient to participate in the study

Exclusion Criteria:

* Non-menopausal patient
* Patient under guardianship, curatorship or deprived of her freedom
* Patient with proven metastases on imaging
* Patient with a macroscopically suspicious cervix
* Patient presenting an ovarian cyst or an associated adnexal pathology
* Patient contraindicated for surgical treatment (therefore not eligible for pathological analysis)
* Patient who has already been treated with hormone therapy for breast cancer
* Patient who has already had surgery for this pathology, with a contributing anatomopathological result (we will therefore include patients who would not benefit from an operative hysteroscopy after performing a cornier® pipelle that does not allow a positive result)

Locations (2)

Saint-Nazaire, Loire-Atlantique, France
La Roche-sur-Yon, Vendee, France